Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

136. Cambridge Innovation Capital Raises £75 Million via Private Financing

Cambridge Innovation Capital Raises £75 Million via Private Financing19/08/2016Cambridge Innovation Capital plc (“CIC” or “the Company”), a preferred investor for the University of Cambridge and a Cambridge-based investor in technology and healthcare companies, announces that it has raised £75m of new capital (the “Fundraising”).CIC was founded in 2013 as an initiative by the University of Cambridge to create a local entity that would be able to prov


137. Consilium Strategic Communications Advises Cambridge Innovation Capita

Consilium Strategic Communications Advises Cambridge Innovation Capital on Its £75m Fundraise 22/08/2016Consilium Strategic Communications, a global leader in strategic healthcare communications, is pleased to have advised Cambridge Innovation Capital (“CIC”) on its over-subscribed £75 million private financing round.CIC is a preferred investor for the University of Cambridge and has a unique relationship with Cambridge Enterprise, the commercialisation arm of the Univ


138. AstraZeneca to Sell Small Molecule Antibiotics Business to Pfizer. Val

AstraZeneca to Sell Small Molecule Antibiotics Business to Pfizer. Value-creating Divestment Supports AstraZeneca’s Focus on Three Main Therapy Areas 24/08/2016> Pfizer’s dedicated focus on infectious diseases will extend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics businessAstraZeneca today announced that it has entered into an agreement with Pfizer Inc. (Pfizer) to sell the commercialisation


139. Vivasure Medical Announces €16.2M ($18.3M) in Financing to Advance Com

Vivasure Medical Announces €16.2M ($18.3M) in Financing to Advance Commercialization of Closure Device in European Union and United States 08/09/2016Vivasure Medical™, a company developing a novel bioabsorbable technology for percutaneous vessel closure, today announced that the company has completed a Series C financing of €16.2M ($18.3M). The round was led by LSP (Life Sciences Partners) of The Netherlands, investing from its LSP Health Economics Fund, and co-led by Evon


140. Emma Walmsley to Succeed Andrew Witty as Chief Executive Officer of Gl

Emma Walmsley to Succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline 20/09/2016GSK today announces that Emma Walmsley, currently Chief Executive Officer (CEO) of GSK’s Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO, when he retires on 31March 2017. Emma will join the GSK Board of Directors from 1 January 2017.Emma is currently CEO of GSK Consumer Healthcare, one of the world’s largest consumer health companies



Page 28 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019